Volume 33, Issue 3 (10-2024)                   JGUMS 2024, 33(3): 310-325 | Back to browse issues page


XML Persian Abstract Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Aghagolzadeh M, Moazedi A, Najafzadehvarzi H, Parsian H. Effects of Rotenone and Resveratrol on Apoptosis and Oxidative Stress in Ovariectomized Rats. JGUMS 2024; 33 (3) :310-325
URL: http://journal.gums.ac.ir/article-1-2614-en.html
1- Department of Biology, Faculty of Science, Shahid Chamran University of Ahvaz, Ahvaz, Iran.
2- Department of Medical Pharmacology, Faculty of Medicine, Babol University of Medical Sciences, Babol, Iran.
3- Department of Clinical Biochemistry, Faculty of Medicine, Babol University of Medical Sciences, Babol, Iran.
Full-Text [PDF 6243 kb]   (324 Downloads)     |   Abstract (HTML)  (1506 Views)
Full-Text:   (461 Views)
Introduction
Neurodegenerative diseases represent a heterogeneous group of disorders that affect millions of people worldwide. These diseases are characterized by the progressive and irreversible loss of function or death of neurons in specific regions of the brain, leading to severe cognitive and functional decline. The most well-known neurodegenerative diseases include Alzheimer disease, Parkinson disease, Huntington disease, and amyotrophic lateral sclerosis, with oxidative stress and apoptosis being the primary shared cellular and molecular mechanisms involved in these neurological disorders [1-3]. Evidence suggests that one of the major contributors to the exacerbation and increased risk of neurodegenerative diseases is environmental neurotoxins, which, in modern societies, are increasingly and uncontrollably threatening the health of living organisms directly or indirectly, thereby raising the risk of disease development [4].
Pesticides are environmental neurotoxins that, upon exposure, increase the risk of neurodegenerative diseases [5، 6]. Rotenone, a naturally occurring insecticide and pesticide derived from leguminous plants, is a potent environmental neurotoxin. Due to its highly lipophilic nature, it readily crosses all biological membranes, including the mitochondrial membrane and the blood-brain barrier, without requiring specific transporters [7-9]. The primary neurotoxic mechanism of rotenone involves inhibiting complex I of the mitochondrial electron transport chain. This inhibition leads to oxidative stress, apoptosis, and impaired autophagy. Rotenone disrupts electron transfer from Fe-S centers in complex I to ubiquinone within the electron transport chain, subsequently inhibiting oxidative phosphorylation, reducing adenosine triphosphate levels, and simultaneously increasing reactive oxygen species production, thereby inducing oxidative stress. Elevated reactive oxygen species levels and oxidative damage to DNA, lipids, and proteins contribute to neuronal cell degeneration [10].
Given the rising incidence of neurodegenerative diseases and the association of various environmental neurotoxins, including rotenone, with neurodegenerative disorders, understanding the inflammatory, apoptotic, and oxidative stress pathways involved in rotenone-induced toxicity is crucial. Moreover, protective mechanisms, such as the neuroprotective role of estrogen and the modulatory effects of resveratrol—a well-known polyphenol with anti-apoptotic, anti-inflammatory, and antioxidant properties—require further exploration. The present study investigates these processes by inducing estrogen depletion (ovariectomy in Wistar rats) and exposing the animals to rotenone, a pesticide commonly used in agriculture, to assess its impact on consumers and agricultural workers. Molecular assessments focused on gene expression changes in Bcl2, BAX, and the antioxidant factor superoxide dismutase (SOD) in the hippocampus of the treated rats.

Methods
This study utilized 30 female Wistar rats (weighing approximately 170±20 g) obtained from the Laboratory Animal Center of Babol University of Medical Sciences (Babol City, Iran). The animals were housed under standard conditions (12-h light/dark cycle, ad libitum access to food and water, and an ambient temperature of 20-25 °C). All experimental procedures were performed following the ethical guidelines set by the Animal Ethics Committee of the Shahid Chamran University of Ahvaz.
The rats were randomly assigned to five groups (n=6 per group). Group 1 was the rotenone group (intraperitoneal injection of 5 mg/kg rotenone; Sigma-Aldrich), group 2 was ovariectomy (OVX) (bilateral ovariectomy), group 3 was OVX + resveratrol group (40 mg/kg resveratrol via gavage), group 4 were OVX + rotenone group, and group 5 were OVX + rotenone + resveratrol group. All treatments were administered daily for three weeks. At the end of the experiment, the animals were anesthetized with intraperitoneal injections of ketamine (80 mg/kg) and xylazine (5 mg/kg) (Alfasan, Netherlands). The hippocampal tissue samples were then collected for analysis.

Statistical analysis
Biochemical assay data were analyzed using IBM SPSS Statistics software, version 20, employing a one-way analysis of variance followed by the Tukey post hoc test. A P<0.05 was considered statistically significant.

Results 
Following ovariectomy, the highest malondialdehyde (MDA) levels were observed in the OVX + rotenone group (40.06±2.22 µM/g), which showed a significant increase compared to the OVX group (32.92±1.12 µM/g; P<0.001). MDA levels in the OVX + resveratrol group (21.42±0.97 µM/g) were significantly lower compared to those in the OVX group (P<0.001). Resveratrol administration significantly reduced MDA levels in the OVX + rotenone + resveratrol group (22.35±1.91 µM/g) compared to the OVX + rotenone group (P<0.001).
SOD activity (16.36±0.61 U/mg) significantly decreased in the OVX + rotenone group compared to the OVX group (70.69±1.58 U/mg; P≤0.001). However, resveratrol administration in the OVX + resveratrol group did not significantly increase SOD activity (77.02±2.2 U/mg) compared to the OVX group. In the OVX + rotenone + resveratrol group, SOD activity (57.9±1.94 U/mg) was significantly higher than in the OVX + rotenone group (P<0.001).
The highest BAX gene expression levels were observed in the OVX + rotenone group (5.9±0.05), which was significantly higher than in the OVX group (1.3±0.11; P<0.001). BAX expression in the OVX + resveratrol group (1.2±0.11) did not significantly differ from the OVX group. However, resveratrol administration significantly reduced BAX expression in the OVX + rotenone + resveratrol group (4.5±0.11) compared to the OVX + rotenone group (P<0.001).
The lowest Bcl2 gene expression levels were recorded in the OVX + rotenone group (0.93±0.05), which was significantly lower than in the OVX group (5.9±0.05; P<0.001). Bcl2 expression in the OVX + resveratrol group (1.13±0.03) did not significantly increase compared to the OVX group. However, resveratrol administration significantly elevated Bcl2 expression in the OVX + rotenone + resveratrol group (0.78±0.05) compared to the OVX + rotenone group (P<0.001).

Conclusion
In this study, rotenone was used as a pesticide-induced neurotoxicant, while ovariectomy (estrogen depletion) was used as an experimental model of menopause. The protective effects of resveratrol against rotenone-induced hippocampal damage were evaluated. The findings demonstrated that rotenone significantly reduced SOD activity and Bcl2 gene expression while increasing MDA levels and BAX gene expression in the hippocampus.
Overall, resveratrol mitigated the neurotoxic effects of rotenone and estrogen depletion on apoptosis and oxidative stress markers. This study supports previous findings that resveratrol supplementation may be beneficial in improving key biomarkers associated with neurodegenerative diseases, particularly in high-risk populations, such as agricultural workers and postmenopausal individuals. Future research should investigate the role of proteins, such as Nrf2, SIRT, and NF-κB, along with their signaling pathways, as well as the effects of estrogen replacement therapy at different concentrations on oxidative stress and apoptosis indices.

Ethical Considerations

Compliance with ethical guidelines

This study was approved by the Ethics Committee of Shahid Chamran University of Ahvaz, Ahvaz, Iran (Code: EE.1400.3.02.10568).

Funding
This research did not receive any grant from funding agencies in the public, commercial, or non-profit sectors.

Authors' contributions 
Conceptualization and study design: Hossein Najafzadehvarzi, AhmadAli Moazedi and Mahboobeh Aghagolzadeh; Data analysis, interpretation, and statistical analysis: Mahboobeh Aghagolzadeh and Hossein Najafzadehvarzi; Financial resources and project administration, technical or material support: AhmadAli Moazedi and Hussain Naj Fazadeh Warzi; Supervision: Hossein Najafzadehvarzi, Ahmad Ali Moazdi, and Hadi Parsian; Writing the original draft: Mahboobeh Aghagolzadeh; Review and editing: All authors.

Conflicts of interest 
The authors declared no conflict of interest.

Acknowledgements
The authors would like to acknowledge the support of the Department of Biology, Shahid Chamran University of Ahvaz, and the Vice Chancellor for Research, Shahid Chamran University of Ahvaz, Ahvaz, Iran and Babol University of Medical Sciences, Babol, Iran during the implementation of this research.




References
  1. Babazadeh A, Vahed FM, Liu Q, Siddiqui SA, Kharazmi MS, Jafari SM. Natural bioactive molecules as neuromedicines for the treatment/prevention of neurodegenerative diseases. ACS Omega. 2023; 8(4):3667-83. [DOI:10.1021/acsomega.2c06098] [PMID]
  2. Davenport F, Gallacher J, Kourtzi Z, Koychev I, Matthews PM, Oxtoby NP, et al. Neurodegenerative disease of the brain: A survey of interdisciplinary approaches. Journal of the Royal Society Interface. 2023; 20(198):20220406. [DOI:10.1098/rsif.2022.0406] [PMID]
  3. Teleanu DM, Niculescu AG, Lungu II, Radu CI, Vladâcenco O, Roza E, et al. An overview of oxidative stress, neuroinflammation, and neurodegenerative diseases. International Journal of Molecular Sciences. 2022; 23(11):5938. [DOI:10.3390/ijms23115938] [PMID]
  4. Richardson JR, Fitsanakis V, Westerink RHS, Kanthasamy AG. Neurotoxicity of pesticides. Acta Neuropathologica. 2019; 138(3):343-62. [DOI:10.1007/s00401-019-02033-9] [PMID]
  5. Sivagurunathan N, Gnanasekaran P, Calivarathan L. Mitochondrial toxicant-induced neuronal apoptosis in Parkinson's Disease: What we know so far. Degenerative Neurological and Neuromuscular Disease. 2023; 13:1-13. [DOI:10.2147/DNND.S361526] [PMID]
  6. Oguh CE, Okpaka CO, Ubani CS, Okekeaji U, Joseph PS, Amadi EU. Natural pesticides (biopesticides) and uses in pest management-A critical review. Asian Journal of Biotechnology and Genetic Engineering. 2019; 2(3):1-18. [Link]
  7. Chiaradia E, Renzone G, Scaloni A, Caputo M, Costanzi E, Gambelunghe A, et al. Protein carbonylation in dopaminergic cells exposed to rotenone. Toxicology Letters. 2019; 309:20-32. [DOI:10.1016/j.toxlet.2019.04.002] [PMID]
  8. Lawana V, Cannon JR. Rotenone neurotoxicity: Relevance to Parkinson's disease. Advances in Neurotoxicology. 2020; 4:209-54. [DOI:10.1016/bs.ant.2019.11.004] 
  9. Pamies D, Block K, Lau P, Gribaldo L, Pardo CA, Barreras P, et al. Rotenone exerts developmental neurotoxicity in a human brain spheroid model. Toxicology and Applied Pharmacology. 2018; 354:101-14. [DOI:10.1016/j.taap.2018.02.003] [PMID]
  10. Sheikhpour E, Mard SA, Farbood Y, Bavarsad K, Sarkaki A. The effects of gallic acid and vagotomy on motor function, intestinal transit, brain electrophysiology and oxidative stress alterations in a rat model of Parkinson's disease induced by rotenone. Life Sciences. 2023; 315:121356. [DOI:10.1016/j.lfs.2022.121356] [PMID] 
  11. Yarmohammadi F, Wallace Hayes A, Najafi N, Karimi G. The protective effect of natural compounds against rotenone‐induced neurotoxicity. Journal of Biochemical and Molecular Toxicology. 2020; 34(12):e22605. [DOI:10.1002/jbt.22605] [PMID] 
  12. Kavuri S, Sivanesan S, Rajagopalan V. Oxidative stress and antioxidant status in rotenone induced rat Model of Parkinson's Disease. International Journal of Research in Pharmaceutical Sciences. 2020; 11(1):1-5. [DOI:10.26452/ijrps.v11i1.1776] 
  13. McCord JM, Edeas MA. SOD, oxidative stress and human pathologies: A brief history and a future vision. Biomedicine & Pharmacotherapy. 2005; 59(4):139-42. [DOI:10.1016/j.biopha.2005.03.005] [PMID]
  14. Aborode AT, Pustake M, Awuah WA, Alwerdani M, Shah P, Yarlagadda R, et al. Targeting oxidative stress mechanisms to treat Alzheimer's and Parkinson's disease: A critical review. Oxidative Medicine and Cellular Longevity. 2022; 2022:7934442. [DOI:10.1155/2022/7934442] [PMID]
  15. Yan W, Wu J, Song B, Luo Q, Xu Y. Retraction Note to: Treatment with a brain-selective prodrug of 17β-estradiol improves cognitive function in Alzheimer's disease mice by regulating klf5-NF-κB pathway. Naunyn-Schmiedeberg's Archives of Pharmacology. 2021; 394(9):1989. [DOI:10.1007/s00210-021-02121-2] [PMID]
  16. Makav M, Eroğlu HA. Recuperative effect of estrogen on rotenone-induced experimental model of Parkinson's disease in rats. Environmental Science and Pollution Research. 2021; 28(17):21266-75. [DOI:10.1007/s11356-020-11985-5] [PMID]
  17. Shvetcov A, Ruitenberg MJ, Delerue F, Gold WA, Brown DA, Finney CA. The neuroprotective effects of estrogen and estrogenic compounds in spinal cord injury. Neuroscience & Biobehavioral Reviews. 2023; 146:105074. [DOI:10.1016/j.neubiorev.2023.105074] [PMID]
  18. Song YJ, Li SR, Li XW, Chen X, Wei ZX, Liu QS, et al. The effect of estrogen replacement therapy on Alzheimer's disease and Parkinson's disease in postmenopausal women: A meta-analysis. Frontiers in Neuroscience. 2020; 14:157. [DOI:10.3389/fnins.2020.00157] [PMID]
  19. Vegeto E, Benedusi V, Maggi A. Estrogen anti-inflammatory activity in brain: A therapeutic opportunity for menopause and neurodegenerative diseases. Frontiers in Neuroendocrinology. 2008; 29(4):507-19. [DOI:10.1016/j.yfrne.2008.04.001] [PMID]
  20. Banks WA. Brain meets body: The blood-brain barrier as an endocrine interface. Endocrinology. 2012; 153(9):4111-9. [DOI:10.1210/en.2012-1435] [PMID]
  21. Won CK, Kim MO, Koh PO. Estrogen modulates Bcl-2 family proteins in ischemic brain injury. Journal of Veterinary Medical Science. 2006; 68(3):277-80. [DOI:10.1292/jvms.68.277] [PMID] 
  22. Torrens-Mas M, Pons DG, Sastre-Serra J, Oliver J, Roca P. Sexual hormones regulate the redox status and mitochondrial function in the brain. Pathological implications. Redox Biology. 2020; 31:101505. [DOI:10.1016/j.redox.2020.101505] [PMID] 
  23. Azam S, Lange T, Huynh S, Aro AR, von Euler-Chelpin M, Vejborg I, et al. Hormone replacement therapy, mammographic density, and breast cancer risk: A cohort study. Cancer Causes & Control. 2018; 29(6):495-505. [DOI:10.1007/s10552-018-1033-0] [PMID]
  24. Cagnacci A, Venier M. The controversial history of hormone replacement therapy. Medicina. 2019; 55(9):602. [DOI:10.3390/medicina55090602] [PMID]
  25. Acero N, Ortega T, Villagrasa V, Leon G, Muñoz‐Mingarro D, Castillo E, et al. Phytotherapeutic alternatives for neurodegenerative dementias: Scientific review, discussion and therapeutic proposal. Phytotherapy Research. 2023; 37(3):1176-211. [DOI:10.1002/ptr.7727] [PMID] 
  26. Luthra R, Roy A. Role of medicinal plants against neurodegenerative diseases. Current Pharmaceutical Biotechnology. 2022; 23(1):123-39. [DOI:10.2174/1389201022666210211123539] [PMID] 
  27. Rana K, Gautam P. A review on antioxidants as therapeutic in use of oxidative stress and neurodegenerative disease. International Journal of Pharmaceutical Quality Assurance. 2022; 13(1):77-82. [Link]
  28. Teleanu RI, Chircov C, Grumezescu AM, Volceanov A, Teleanu DM. Antioxidant therapies for neuroprotection-A review. Journal of Clinical Medicine. 2019; 8(10):1659. [DOI:10.3390/jcm8101659] [PMID]
  29. Fonseca-Santos B, Chorilli M. The uses of resveratrol for neurological diseases treatment and insights for nanotechnology based-drug delivery systems. International Journal of Pharmaceutics. 2020; 589:119832. [DOI:10.1016/j.ijpharm.2020.119832] [PMID]
  30. Meng T, Xiao D, Muhammed A, Deng J, Chen L, He J. Anti-inflammatory action and mechanisms of resveratrol. Molecules. 2021; 26(1):229. [DOI:10.3390/molecules26010229] [PMID]
  31. Gu J, Li Z, Chen H, Xu X, Li Y, Gui Y. Neuroprotective effect of trans-resveratrol in mild to moderate Alzheimer disease: A randomized, double-blind trial. Neurology and Therapy. 2021; 10(2):905-17. [DOI:10.1007/s40120-021-00271-2] [PMID]
  32. Jardim FR, de Rossi FT, Nascimento MX, da Silva Barros RG, Borges PA, Prescilio IC, et al. Resveratrol and brain mitochondria: A review. Molecular Neurobiology. 2018; 55(3):2085-101. [DOI:10.1007/s12035-017-0448-z] [PMID]
  33. Gomes BAQ, Silva JPB, Romeiro CFR, Dos Santos SM, Rodrigues CA, Gonçalves PR, et al. Neuroprotective mechanisms of resveratrol in Alzheimer's disease: Role of SIRT1. Oxidative Medicine and Cellular Longevity. 2018; 2018:8152373.[DOI:10.1155/2018/8152373] [PMID]
  34. Acungil ZK, Nacar T. Effect of resveratrol on a penicillin-induced epilepsy model in rats. Archives of Epilepsy. 2022; 28(2):78-84. [Link]
  35. Chinraj V, Raman S. Neuroprotection by resveratrol: A review on brain delivery strategies for Alzheimer's and Parkinson's disease. Journal of Applied Pharmaceutical Science. 2022; 12(7):001-17. [DOI:10.7324/JAPS.2022.120701] 
  36. Kung HC, Lin KJ, Kung CT, Lin TK. Oxidative stress, mitochondrial dysfunction, and neuroprotection of polyphenols with respect to resveratrol in Parkinson's disease. Biomedicines. 2021; 9(8):918. [DOI:10.3390/biomedicines9080918] [PMID]
  37. Sarroca S, Gatius A, Rodríguez-Farré E, Vilchez D, Pallàs M, Griñán-Ferré C, et al. Resveratrol confers neuroprotection against high-fat diet in a mouse model of Alzheimer's disease via modulation of proteolytic mechanisms. The Journal of Nutritional Biochemistry. 2021; 89:108569. [DOI:10.1016/j.jnutbio.2020.108569] 
  38. Zamora-Bello I, Rivadeneyra-Domínguez E, Rodríguez-Landa JF. Anticonvulsant effect of turmeric and resveratrol in lithium/pilocarpine-induced status epilepticus in wistar rats. Molecules. 2022; 27(12):3835. [DOI:10.3390/molecules27123835] 
  39. Truong VL, Jun M, Jeong WS. Role of resveratrol in regulation of cellular defense systems against oxidative stress. Biofactors. 2018; 44(1):36-49. [DOI:10.1002/biof.1399] [PMID]
  40. Wang H, Dong X, Liu Z, Zhu S, Liu H, Fan W, et al. Resveratrol suppresses rotenone‐induced neurotoxicity through activation of SIRT1/Akt1 signaling pathway. The Anatomical Record. 2018; 301(6):1115-25. [DOI:10.1002/ar.23781] [PMID]
  41. Sharifi F, Reisi P, Malek M. The effects of estrogen on passive avoidance memory impairment induced by acute kidney injury in ovariectomized rats. Journal of Isfahan Medical School. 2019; 37(515):86-92. [DOI:10.22122/jims.v37i515.11140]
  42. Cannon JR, Tapias V, Na HM, Honick AS, Drolet RE, Greenamyre JT. A highly reproducible rotenone model of Parkinson's disease. Neurobiology of Disease. 2009; 34(2):279-90. [DOI:10.1016/j.nbd.2009.01.016] [PMID]
  43. Jiang XW, Qiao L, Feng XX, Liu L, Wei QW, Wang XW, et al. Rotenone induces nephrotoxicity in rats: Oxidative damage and apoptosis. Toxicology Mechanisms and Methods. 2017; 27(7):528-36. [DOI:10.1080/15376516.2017.1333553] [PMID]
  44. Abdu SB, Al-Bogami FM. Influence of resveratrol on liver fibrosis induced by dimethylnitrosamine in male rats. Saudi Journal of Biological Sciences. 2019; 26(1):201-9. [DOI:10.1016/j.sjbs.2017.09.003] [PMID]
  45. Genet S, Kale RK, Baquer NZ. Alterations in antioxidant enzymes and oxidative damage in experimental diabetic rat tissues: effect of vanadate and fenugreek (Trigonella foenum graecum). Molecular and Cellular Biochemistry. 2002; 236(1-2):7-12. [DOI:10.1023/A:1016103131408] [PMID]
  46. Cheng YJ, Lin CH, Lane HY. From menopause to neurodegeneration-molecular basis and potential therapy. International Journal of Molecular Sciences. 2021; 22(16):8654. [DOI:10.3390/ijms22168654] [PMID]
  47. Luine V, Frankfurt M. Estrogenic regulation of memory: The first 50 years. Hormones and Behavior. 2020; 121:104711. [DOI:10.1016/j.yhbeh.2020.104711] [PMID]
  48. Saeed K, Jo MH, Park JS, Alam SI, Khan I, Ahmad R, et al. 17β-Estradiol abrogates oxidative stress and neuroinflammation after cortical stab wound injury. Antioxidants. 2021; 10(11):1682. [DOI:10.3390/antiox10111682] [PMID]
  49. Shen D, Tian X, Zhang B, Song R. Mechanistic evaluation of neuroprotective effect of estradiol on rotenone and 6-OHDA induced Parkinson's disease. Pharmacological Reports. 2017; 69(6):1178-85. [DOI:10.1016/j.pharep.2017.06.008] [PMID]
  50. Baur JA, Sinclair DA. Therapeutic potential of resveratrol: The in vivo evidence. Nature Reviews Drug Discovery. 2006; 5(6):493-506. [DOI:10.1038/nrd2060] [PMID]
  51. Kumar A, Singh CK, LaVoie HA, DiPette DJ, Singh US. Resveratrol restores Nrf2 level and prevents ethanol-induced toxic effects in the cerebellum of a rodent model of fetal alcohol spectrum disorders. Molecular Pharmacology. 2011; 80(3):446-57. [DOI:10.1124/mol.111.071126] [PMID]
  52. Auti A, Alessio N, Ballini A, Dioguardi M, Cantore S, Scacco S, et al. Protective effect of resveratrol against hypoxia-induced neural oxidative stress. Journal of Personalized Medicine. 2022; 12(8):1202. [DOI:10.3390/jpm12081202] [PMID]
Review Paper: Research | Subject: Special
Received: 2023/05/12 | Accepted: 2024/02/21 | Published: 2024/10/1

Add your comments about this article : Your username or Email:
CAPTCHA

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2025 CC BY-NC 4.0 | Journal of Guilan University of Medical Sciences

Designed & Developed by : Yektaweb